Eli Lilly and Company, Johnson & Johnson, Regeneron Pharmaceuticals, AbbVie, and Merck & Co., Inc. are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares in companies that research, develop, manufacture, or sell prescription and other medicines. For investors, their value can be affected by factors such as clinical-trial results, regulatory approvals, patent protection, competition, and demand for treatments. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE LLY traded down $4.36 during mid-day trading on Wednesday, reaching $1,427.93. The company had a trading volume of 704,361 shares, compared to its average volume of 2,958,567. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a market capitalization of $1.34 trillion, a price-to-earnings ratio of 46.32, a PEG ratio of 1.69 and a beta of 0.40. The stock has a fifty day moving average of $1,225.57 and a two-hundred day moving average of $1,104.56. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,453.00.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Johnson & Johnson stock traded down $2.96 during trading hours on Wednesday, hitting $277.82. The company had a trading volume of 1,720,349 shares, compared to its average volume of 7,938,919. The firm has a market capitalization of $668.80 billion, a P/E ratio of 42.10, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm's fifty day moving average is $266.49 and its 200-day moving average is $248.93. Johnson & Johnson has a fifty-two week low of $193.07 and a fifty-two week high of $283.25.
Read Our Latest Research Report on JNJ
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
REGN stock traded up $13.10 during midday trading on Wednesday, reaching $929.16. The company had a trading volume of 442,560 shares, compared to its average volume of 831,660. The company has a 50 day moving average of $809.24 and a two-hundred day moving average of $744.46. The company has a market capitalization of $96.12 billion, a P/E ratio of 20.52, a PEG ratio of 1.22 and a beta of 0.10. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $991.73. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.
Read Our Latest Research Report on REGN
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of AbbVie stock traded down $1.91 on Wednesday, hitting $291.98. 1,213,371 shares of the company traded hands, compared to its average volume of 6,309,129. AbbVie has a 12-month low of $190.75 and a 12-month high of $302.93. The company has a market cap of $516.10 billion, a PE ratio of 50.27, a PEG ratio of 1.33 and a beta of 0.20. The company has a 50-day moving average price of $273.45 and a 200 day moving average price of $239.80.
Read Our Latest Research Report on ABBV
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of NYSE:MRK traded down $1.92 during midday trading on Wednesday, hitting $146.13. 2,006,541 shares of the stock were exchanged, compared to its average volume of 10,572,838. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. Merck & Co., Inc. has a 52-week low of $90.90 and a 52-week high of $156.92. The business's fifty day simple moving average is $146.39 and its two-hundred day simple moving average is $128.02. The company has a market capitalization of $360.25 billion, a PE ratio of 150.59, a P/E/G ratio of 6.78 and a beta of 0.13.
Read Our Latest Research Report on MRK
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
